Dalton Pharma and Boehringer Ingelheim Announce the Renewal of Chemistry Services Agreement
News Feb 24, 2009
Dalton Pharma Services announces the renewal of its Chemistry Services Agreement with Boehringer Ingelheim (Canada) Ltd.
Under the agreement Dalton will continue to provide chemistry services in support of Boehringer’s pharmaceutical development programs.
Peter Pekos, President of Dalton Pharma Services, said: “We are extremely pleased to continue our relationship with Boehringer Ingelheim (Canada) Ltd. The renewal of our chemistry services agreement demonstrates Boehringer Ingelheim’s deep commitment to research in Canada. We look forward to another successful collaboration with this world class organization.”
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
WuXi Biologics to Invest in Biologics Manufacturing Facility in SingaporeNews
WuXi Biologics' first overseas site in Asia.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018